Sri LankaTuberculosis profile
Population  2016 21 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.2 (0.89–1.7) 6 (4.3–8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.03 (0.02–0.04)
Incidence  (includes HIV+TB) 13 (9.9–18) 65 (48–84)
Incidence (HIV+TB only) 0.02 (0.015–0.027) 0.1 (0.07–0.13)
Incidence (MDR/RR-TB)** 0.093 (0–0.2) 0.45 (0–0.95)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.69 (0.49–0.88) 4 (2.9–5.2) 4.7 (3.4–6.1)
Males 0.78 (0.56–1) 8 (5.7–10) 8.7 (6.3–11)
Total 1.5 (1–1.9) 12 (8.6–15) 13 (9.9–18)
TB case notifications, 2016  
Total cases notified 8 886
Total new and relapse 8 664
          - % tested with rapid diagnostics at time of diagnosis 19%
          - % with known HIV status 89%
          - % pulmonary 70%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 64% (49–87)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.1 (0.06–0.14)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 12 <1%
          - on antiretroviral therapy 7 58%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  47
(1–93)
Estimated % of TB cases with MDR/RR-TB 0.54% (0–1.3) 3.1% (1.6–5.4)  
% notified tested for rifampicin resistance 15% 47% 1 511
MDR/RR-TB cases tested for resistance to second-line drugs   11
Laboratory-confirmed cases MDR/RR-TB: 23, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 17, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 85% 9 293
Previously treated cases, excluding relapse, registered in 2015 68% 282
HIV-positive TB cases registered in 2015 76% 25
MDR/RR-TB cases started on second-line treatment in 2014 69% 13
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 10%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
27% (25–30)
TB financing, 2017  
National TB budget (US$ millions) 16
Funding source: 34% domestic, 24% international, 42% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data